Tryp Therapeutics President Interview (CSE: TRYP) (OTCQB:TRYPF) – RICH TV LIVE – July 14, 2021 – Tryp Therapeutics (CSE: TRYP) (OTCQB:TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with the University of Michigan to perform research related to Tryp’s Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program.
Do you want to learn how to trade stocks in cryptocurrency join our community of traders go to richpixdaily.com and find the next 10 bagger hi how’s everybody doing today i’m your host rich here and we have a rich tv live with our very special guest jim gilligan the president and cso of trip therapeutics how you doing today jim thank you yourself i’m
Doing fantastic thank you for joining us on our show today yeah i’m excited about the opportunity hey my pleasure very excited to learn more about trip therapeutics and our community really likes trip therapeutics and a lot of our members have already started taking positions in the company can you tell us a little bit about trip therapeutics and how it is
A drug development company focused on developing compounds with established safety profiles and medical utilities for the treatment of rare diseases and other diseases with few or no treatment options what else should investors know about your company that’s a great question one of the things i think that distinguishes trip from maybe some of the others in
The sector is that we have what we might be considered pharmaceutical or biotech executives associated with the company we’ve all been involved in the process of taking drugs from inception through to regulatory approval and it’s it’s not easy it’s it’s not an easy path in order to be successful and what you’re trying to do right is remove risk and we’ll
Come back to risk in a number of the questions and discussion and by having a group with the requisite experience that we have we remove the risk from the actual uh uh regulatory execution stage and give the molecule the best chance for success wow that’s fantastic and why did trip therapeutics choose to get involved in the psychedelic therapy space you
Know i had a phd in pharmacology and what you realize when a number of disease entities in states is that when we develop drugs many times it’s for symptomatic relief we address the symptoms and not necessarily the cause of the disease and one of the advantages that’s been seen in early research with cytosimin is the fact that a single intervention or maybe
Dual intervention gives a profound effect with duration for months and it seems to go a little bit further upstream and correct some of the the problems that are the cause of the disease and not just the symptomatology that’s fantastic thank you for that and can you please tell us a little bit about your progress trip has made in using psilocybin to target
Treatment for eating disorders so yeah so we’re working with dr jennifer miller at university of florida who’s a world-renowned expert in eating disorders and part of the trip strategy approach has been is we should go out and find the true experts in the field for an example eating disorder and they bring that expertise to the table where we bring the drug
Development and the psychedelic expertise to the table and when you marry coalesce those two and bring those two together again it gives us the best chance for success and so that hence that’s why we forged this relationship with dr miller university of florida very good so jim how is tripp able to shorten development and approval times while reducing the cost
Of a development programs that’s a great question um there’s there’s an opportunity that’s called the 505b2 with respect to the fda and fda has has set this out for drugs or molecules that have existing safety or efficacy data and in the case with psilocybin we have both of those and so it allows a company to proceed immediately into your phase two studies
And start treating with patients and not begin to start from the beginning so that improves both time and cost moving your program forward what are the advantages and opportunities presented by targeting rare orphan diseases so that’s primarily a regulatory advantage and what it allows you to do is to get an expedited review by the fda and it also will give
You a longer period of exclusivity and since a number of or several of the disease entities who are targeting would meet the drug criteria so it behooves us to take advantage of the ability to accelerate review getting fda’s attention and then having uh potentially a longer period of exclusivity what advantages might trip 1001 have for treating soft tissue
Sarcomas over existing treatments so one of the things that unfortunately in the area of soft tissue sarcoma is there haven’t been a number of advances for brand new monotherapies the the trip 1001 we’ve gone back and looked at its historical performance and again here’s another drug that has demonstrated safety and efficacy so we can move forward as they
Say with the lacquer we can move forward quickly what’s what’s happened here is a perfect coalescence of understanding now how this molecule works with new advances in understanding human biology and what uh some of the studies have shown is that if you combine our drug resoxane with other chemotherapeutic agents or radiation it greatly reduces the incidence
Of metastasis and improves the response to the current therapeutic drug so we’re not looking at it as a standalone model therapy but rather to add it to existing standard of care which can improve outcomes very good very good why does trip see potential in psilocybin for treating eating disorders so just just as we’re looking at things in neuropathic pain
Where we know that the pain emanates from the brain we’re selecting areas with eating disorders where again they think that there’s a neurologic component that the compulsion to eat comes from the brain and that we think that uh given the fact that cytosine has had uh success in other areas of addiction like alcohol addiction even cigarette smoking that
This could be potentially in other areas where integrated into psychotherapy plus psilocybin could beneficial effect in eating disorders and some of these are really terrible diseases and these people have what’s called hyperphagia where even when they eat they don’t feel satisfied they continue to eat they continue to eat and when you speak with dr miller
She has patients who said that you know the parents are trying to do the best thing and they’ll leave the house and literally go in to restaurant dumpsters to find additional food so it’s a tragic disorder and that’s why we really feel and hope that silence hot therapy will have a positive impact for these patients so i know that you guys are listing on the
Otcqb what would that mean for the company i think you know what we’re trying to do is get a broader audience a broader number of people facilitating their opportunity we think that we have an exciting future and certainly whatever you do to make it easier for people to make investment participate but trip at this stage we’ll think he’s an advantage and
Again remember i’m just a science guy so you know i’m just keeping you from the science now we have investors that have taken interest in trip from all over the world that have already been messaging me saying that they’re taking positions and they feel it’s undervalued how can an investor that’s interested in learning more about the company get in contact
With you so i think you know from investment perspective you know we have greg mckee who is our ceo we should be great at trip therapeutics.com we have our chief financial officer luke cage who again it’s pretty simple look at therapeutics.com and if you have a tough science question you can always get me at jay gilligan at tripthoughpenix.com fantastic well
You know what we’re really excited to see you guys grow and evolve thank you for joining us today jim oh thank you appreciate you having me my pleasure now before we say goodbye i want everyone to know that rich tv live is strictly for information and education purposes please do your due diligence do your research before you invest in anything that we talk
About here rich tv live i do believe that this is a company that is doing great work i do think that it is undervalued under appreciated and underexposed if you like the video please smash the like button comment down below share the video everywhere and subscribe thank you for your time today jim thank you for watching everybody and have a nice day you
Transcribed from video
Tryp Therapeutics President Interview (CSE: TRYP) (OTCQB:TRYPF) By RICH TV LIVE
